In 2019, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this therapy area totaled approximately $3.5 billion. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics in the immunology space are set to lose patent protection, and biosimilars will launch and reduce branded biologics’ patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Immunology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Immune Biologics
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of Immune Biological Brands in Forecast
          • Overview of Approved Immune Biologics
          • Biosimilar Entry Assumptions for Immune Biologics
        • Overview of Biosimilars in Immune Disease Assumptions
        • Drug-Specific Forecast Assumptions
          • Remicade
            • Outlook for Remicade
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Remicade: United States
            • Patient Share by Specialty for Remicade: EU5
            • Patient Share by Specialty for Remicade: Japan
            • Remicade Sales Forecast for the United States: 2019-2029
            • Remicade Sales Forecast for the EU5: 2019-2029
            • Remicade Sales Forecast for Japan: 2019-2029
          • Enbrel
            • Outlook for Enbrel
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Enbrel: United States
            • Patient Share by Specialty for Enbrel: EU5
            • Patient Share by Specialty for Enbrel: Japan
            • Enbrel Sales Forecast for the United States: 2019-2029
            • Enbrel Sales Forecast for the EU5: 2019-2029
            • Enbrel Sales Forecast for Japan: 2019-2029
          • Rituxan / MabThera
            • Outlook for Rituxan / MabThera
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Rituxan Sales Forecast for the United States (Immunology): 2019-2029
            • MabThera Sales Forecast for the EU5 (Immunology): 2019-2029
            • Rituxan Sales Forecast for the United States (Immunology and Oncology): 2019-2029
            • MabThera Sales Forecast for the EU5 (Immunology and Oncology): 2019-2029
          • Humira
            • Outlook for Humira
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Humira: United States
            • Patient Share by Specialty for Humira: EU5
            • Patient Share by Specialty for Humira: Japan
            • Humira Sales Forecast for the United States: 2019-2029
            • Humira Sales Forecast for the EU5: 2019-2029
            • Humira Sales Forecast for Japan: 2019-2029
          • Actemra / RoActemra
            • Outlook for Actemra / RoActemra
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Actemra Sales Forecast for the United States: 2019-2029
            • RoActemra Sales Forecast for the EU5: 2019-2029
            • Actemra Sales Forecast for Japan: 2019-2029
          • Stelara
            • Outlook for Stelara
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Stelara: United States
            • Patient Share by Specialty for Stelara: EU5
            • Patient Share by Specialty for Stelara: Japan
            • Stelara Sales Forecast for the United States: 2019-2029
            • Stelara Sales Forecast for the EU5: 2019-2029
            • Stelara Sales Forecast for Japan: 2019-2029
          • Cimzia
            • Outlook for Cimzia
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Cimzia: United States
            • Patient Share by Specialty for Cimzia: EU5
            • Patient Share by Specialty for Cimzia: Japan
            • Cimzia Sales Forecast for the United States: 2019-2029
            • Cimzia Sales Forecast for the EU5: 2019-2029
            • Cimzia Sales Forecast for Japan: 2019-2029
          • Simponi
            • Outlook for Simponi
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Simponi: United States
            • Patient Share by Specialty for Simponi: EU5
            • Patient Share by Specialty for Simponi: Japan
            • Simponi Sales Forecast for the United States: 2019-2029
            • Simponi Sales Forecast for the EU5: 2019-2029
            • Simponi Sales Forecast for Japan: 2019-2029
          • Orencia
            • Outlook for Orencia
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Orencia Sales Forecast for the United States: 2019-2029
            • Orencia Sales Forecast for the EU5: 2019-2029
            • Orencia Sales Forecast for Japan: 2019-2029
          • Cosentyx
            • Outlook for Cosentyx
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Cosentyx: United States
            • Patient Share by Specialty for Cosentyx: Japan
            • Cosentyx Sales Forecast for the United States: 2019-2029
            • Cosentyx Sales Forecast for Japan: 2019-2029
          • Taltz
            • Outlook for Taltz
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Patient Share by Specialty for Taltz: United States
            • Taltz Sales Forecast for the United States: 2019-2029
          • Entyvio
            • Outlook for Entyvio
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Entyvio Sales Forecast for the United States: 2019-2029
            • Entyvio Sales Forecast for the EU5: 2019-2029
            • Entyvio Sales Forecast for Japan: 2019-2029

      Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

      Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

      Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.